T. Rowe Price Associates’s Ascendis Pharma A/S ASND Stock Holding History

T. Rowe Price Associates’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$350M	Sell	1,530,345 -39,915	-3%	-$8.95M	0.04%	328
2025 Q4	$335M	Sell	1,570,260 -155,968	-9%	-$32.2M	0.04%	329
2025 Q3	$343M	Sell	1,726,228 -149,263	-8%	-$27.8M	0.04%	335
2025 Q2	$324M	Sell	1,875,491 -380,611	-17%	-$62M	0.04%	336
2025 Q1	$352M	Sell	2,256,102 -27,105	-1%	-$3.87M	0.04%	321
2024 Q4	$314M	Buy	2,283,207 +162,079	+8%	+$21.3M	0.04%	343
2024 Q3	$317M	Buy	2,121,128 +336,980	+19%	+$45.5M	0.04%	350
2024 Q2	$243M	Buy	1,784,148 +2,222	+0.1%	+$302K	0.03%	383
2024 Q1	$269M	Buy	1,781,926 +336,976	+23%	+$48.1M	0.03%	371
2023 Q4	$182M	Sell	1,444,950 -192,898	-12%	-$19.2M	0.02%	431
2023 Q3	$153M	Sell	1,637,848 -419,316	-20%	-$39.2M	0.02%	442
2023 Q2	$184M	Sell	2,057,164 -1,312,779	-39%	-$114M	0.03%	404
2023 Q1	$361M	Sell	3,369,943 -339,898	-9%	-$38.9M	0.05%	287
2022 Q4	$453M	Sell	3,709,841 -165,022	-4%	-$19.2M	0.07%	250
2022 Q3	$400M	Sell	3,874,863 -1,290,512	-25%	-$122M	0.07%	255
2022 Q2	$480M	Buy	5,165,375 +295,224	+6%	+$27.8M	0.06%	297
2022 Q1	$572M	Buy	4,870,151 +108,958	+2%	+$12.6M	0.06%	304
2021 Q4	$641M	Sell	4,761,193 -74,521	-2%	-$11.1M	0.06%	305
2021 Q3	$771M	Sell	4,835,714 -225,540	-4%	-$30.9M	0.07%	268
2021 Q2	$666M	Sell	5,061,254 -12,082	-0.2%	-$1.61M	0.06%	295
2021 Q1	$654M	Sell	5,073,336 -1,545,706	-23%	-$235M	0.07%	293
2020 Q4	$1.1B	Sell	6,619,042 -158,593	-2%	-$26.2M	0.11%	193
2020 Q3	$1.05B	Sell	6,777,635 -286,749	-4%	-$41.2M	0.12%	180
2020 Q2	$1.04B	Sell	7,064,384 -128,445	-2%	-$17.6M	0.13%	162
2020 Q1	$810M	Sell	7,192,829 -568,467	-7%	-$73.9M	0.13%	167
2019 Q4	$1.08B	Sell	7,761,296 -13,696	-0.2%	-$1.52M	0.14%	152
2019 Q3	$749M	Buy	7,774,992 +596,956	+8%	+$66.6M	0.11%	208
2019 Q2	$827M	Buy	7,178,036 +2,509,034	+54%	+$300M	0.12%	194
2019 Q1	$550M	Buy	4,669,002 +558,110	+14%	+$48.9M	0.08%	242
2018 Q4	$258M	Buy	4,110,892 +729,096	+22%	+$45.8M	0.04%	368
2018 Q3	$240M	Buy	3,381,796 +282,697	+9%	+$19.5M	0.04%	438
2018 Q2	$206M	Buy	3,099,099 +281,261	+10%	+$18.5M	0.03%	475
2018 Q1	$184M	Buy	2,817,838 +2,363,868	+521%	+$133M	0.03%	482
2017 Q4	$18.2M	Buy	+453,970	New	+$16.5M	﹤0.01%	1223

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates's ASND Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Ascendis Pharma A/S (ASND) stake by 2.5% in Q1 2026, selling an estimated $8.95M and leaving 1,530,345 shares worth $350M. The position accounts for 0.04% of the portfolio, ranked #328.

T. Rowe Price Associates first reported a position in ASND in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.1B in Q4 2020. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

T. Rowe Price Associates held 1,530,345 shares of Ascendis Pharma A/S worth $350M as of Q1 2026.
T. Rowe Price Associates sold 39,915 Ascendis Pharma A/S shares in Q1 2026, an estimated $8.95M.
Ascendis Pharma A/S made up 0.04% of T. Rowe Price Associates's portfolio in Q1 2026, its #328 holding.
T. Rowe Price Associates first reported a position in Ascendis Pharma A/S in Q4 2017 and has held it in 34 quarters since.
T. Rowe Price Associates's Ascendis Pharma A/S position peaked at $1.1B in Q4 2020.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.